Evidence-Based Data About Prevalence and Risk of Malignancy of Thyroid Incidentalomas Detected by Different PET Radiopharmaceuticals.

Giovanni Signore, Domenico Albano, Luca Giovanella, Francesco Bertagna, Giorgio Treglia

Journal: Current radiopharmaceuticals 2021;13(2):89-93

PMID: 31830891

Free Full Text on Elsevier Science View on PubMed

Abstract

BACKGROUND

To date, several meta-analyses and systematic reviews have reported data about the prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals.

OBJECTIVE

This article aims to summarize the published evidence-based data about the prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals.

METHODS

A comprehensive computer literature search of systematic reviews and meta-analyses published up to July 2019 in PubMed/MEDLINE and Cochrane library databases regarding the prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals was carried out.

RESULTS

We have summarized the data about prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals (fluorine-18 fluorodeoxyglucose, radiolabelled choline and prostate-specific membrane antigen) taking into account 8 evidence-based articles.

CONCLUSION

Evidence-based data demonstrated that thyroid incidentalomas detected by different PET radiopharmaceuticals are not infrequent and their risk of malignancy is not negligible, in particular if focal pattern is evident at PET, thus requiring further clinical and instrumental evaluation.

Address: School of Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.; Nuclear Medicine, University of Brescia and Spedali Civili of Brescia, Brescia, Italy.; Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona/Lugano, Switzerland.; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; Health Technology Assessment Unit, Academic Education, Research and Innovation Area, General Directorate, Ente Ospedaliero Cantonale, Bellinzona, Switzerland

DOI: 10.2174/1874471012666191212115732

Link outs

Free resources

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/CRP-E...

Medical:

https://medlineplus.gov/thyroidcancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Evidence-Based Medicine, Humans, Incidental Findings, Positron-Emission Tomography, Prevalence, Thyroid Gland, Thyroid Neoplasms